Sutro Biopharma (STRO) Total Liabilities (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Total Liabilities data on file, last reported at $306.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 10.6% year-over-year to $306.3 million; the trailing twelve-month figure through Dec 2025 stood at $306.3 million (down 10.6% YoY), and the FY2025 full-year result was $306.3 million, down 10.6% from the prior year.
• Total Liabilities grew to $306.3 million in Q4 2025, from $296.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $347.2 million in Q1 2025 to a low of $51.2 million in Q1 2021.
• A 5-year average of $229.7 million and a median of $295.7 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities decreased 28.69% in 2021 and jumped 237.67% in 2022, its largest moves.
• Tracing STRO's Total Liabilities over 5 years: stood at $88.8 million in 2021, then soared by 113.74% to $189.9 million in 2022, then surged by 69.09% to $321.1 million in 2023, then climbed by 6.7% to $342.6 million in 2024, then slipped by 10.6% to $306.3 million in 2025.
• Business Quant data shows STRO's Total Liabilities at $306.3 million in Q4 2025, $296.9 million in Q3 2025, and $294.5 million in Q2 2025.